Promising drug trial offers hope for rare, severe skin condition
NCT ID NCT06444399
First seen Feb 14, 2026 · Last updated May 06, 2026 · Updated 17 times
Summary
This study tests whether the drug deucravacitinib can safely and effectively treat pityriasis rubra pilaris (PRP), a rare skin disease that causes red, scaly patches. About 12 adults with moderate to severe PRP will take the drug for 24 weeks. Researchers will measure changes in skin severity, itching, and quality of life, and look for biological markers that might predict who responds best.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITYRIASIS RUBRA PILARIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Conditions
Explore the condition pages connected to this study.